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B-cell acute lymphoblastic leukemia is the commonest childhood cancer.In infants, B-cell acute lymphoblastic leukemia remains fatal, especiallyin patients with t(4;11), present in ~80% of cases. The pathogenesis of
t(4;11)/KMT2A-AFF1+ (MLL-AF4+) infant B-cell acute lymphoblastic leukemia
remains difficult to model, and the pathogenic contribution in cancer of the
reciprocal fusions resulting from derivative translocated-chromosomes
remains obscure. Here, “multi-layered” genome-wide analyses and validation
were performed on a total of 124 de novo cases of infant B-cell acute lym-
phoblastic leukemia uniformly diagnosed and treated according to the
Interfant 99/06 protocol. These patients showed the most silent mutational
landscape reported so far for any sequenced pediatric cancer. Recurrent muta-
tions were exclusively found in K-RAS and N-RAS, were subclonal and were
frequently lost at relapse, despite a larger number of non-recurrent/non-silent
mutations. Unlike non-MLL-rearranged B-cell acute lymphoblastic
leukemias, B-cell receptor repertoire analysis revealed minor, non-expanded
B-cell clones in t(4;11)+ infant B-cell acute lymphoblastic leukemia, and RNA-
sequencing showed transcriptomic similarities between t(4;11)+ infant B-cell
acute lymphoblastic leukemias and the most immature human fetal liver
hematopoietic stem and progenitor cells, confirming a “pre-VDJ” fetal cellular
origin for both t(4;11) and RASmut. The reciprocal fusion AF4-MLL was
expressed in only 45% (19/43) of the t(4;11)+ patients, and HOXA cluster
genes are exclusively expressed in AF4-MLL-expressing patients. Importantly,
AF4-MLL/HOXA-expressing patients had a significantly better 4-year event-
free survival (62.4% vs. 11.7%, P=0.001), and overall survival (73.7 vs. 25.2%,
P=0.016). AF4-MLL expression retained its prognostic significance when ana-
lyzed in a Cox model adjusting for risk stratification according to the
Interfant-06 protocol based on age at diagnosis, white blood cell count and
response to prednisone. This study has clinical implications for disease out-
come and diagnostic risk-stratification of t(4;11)+ infant B-cell acute lym-
phoblastic leukemia.
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ABSTRACT
Introduction
B-cell precursor acute lymphoblastic leukemia (BCP-
ALL) is the most frequent cancer in children.1 Current 5-
year survival rates in pediatric BCP-ALL approach 90%.
However, BCP-ALL in infants (iBCP-ALL; <1 year of age)
remains clinically challenging with an aggressive early
clinical presentation in uniquely vulnerable hosts.2
Approximately 80% of iBCP-ALL are diagnosed with
chromosomal rearrangements involving the mixed-lin-
eage leukemia (KMTA2, also called MLL) gene, located
on 11q23,3–5 which confers a dismal prognosis especially
in patients carrying the t(4;11)/KMT2A-AFF1+ (MLL-
AF4+).6–8
MLL is a H3K4 histone methyltransferase required for
normal hematopoiesis and HOX gene expression.9,10
Leukemia transformation by MLL fusions requires the
recruitment of the H3K79 histone methyltransferase
Dot1L to the MLL transcriptional complex.11,12 Indeed, an
H3K79 methylation profile defines both mouse and
human t(4;11)/MLL-AF4+ BCP-ALL.13 Importantly, MLL
rearrangements (MLLr) occur prenatally during embryon-
ic/fetal hematopoiesis, and the concordance rate for
iBCP-ALL in identical twins with a monochorionic pla-
centa is close to 100%.14–17 This, coupled to the extremely
short latency, suggests that MLL fusions might be suffi-
cient for leukemogenesis.4 Accordingly, genome-wide
studies using both single nucleotide polymorphism
arrays and whole-genome sequencing revealed that
MLLr iBCP-ALL has a very low frequency of somatic
mutations with the predominant clone carrying ~1.3
non-silent mutations and one copy number alteration.18–
20 Although these studies were performed at low cover-
age sequencing they reinforce the concept that MLLr
iBCP-ALL requires few additional mutations to induce
full transformation. In contrast, MLL-AF4-induced leuke-
mogenesis has proven difficult to model.4,9 With the
exception of a recent work by Lin et al.21,22 who fused
human MLL to murine Af4, creating an artificial leuke-
mogenic human-mouse chimeric fusion, current murine
and humanized models of MLL-AF4+ BCP-ALL do not
faithfully recapitulate the disease pathogenesis/pheno-
type, suggesting that MLL-AF4 per se is insufficient to ini-
tiate leukemogenesis.23–28
The few mutations and copy number alterations pres-
ent in MLLr iBCP-ALL seem subclonal and not always
retained at relapse.20 Intratumor heterogeneity drives
clonal evolution in response to microenvironmental cues
and cytotoxic treatment and therefore recurrent muta-
tions at diagnosis and relapse may be found in minor but
clinically relevant subclones.29 Here we aimed to address
the clinical relevance of subclonal mutations and gene
expression signatures in a large cohort of iBCP-ALL. To
do this, we performed deeper exome sequencing along
with whole-genome DNA- and RNA-sequencing on a
large cohort of 50 MLLr and non-MLL iBCP-ALL patients
uniformly treated and followed up according to an
Interfant treatment protocol.30 Similarly to Anderson et
al.,20 we report a silent mutational landscape in iBCP-ALL
irrespective of the MLL rearrangement/status. However,
strikingly, our genome-wide DNA and RNA analyses
revealed new, clinically relevant information about dis-
ease outcome and cell-of-origin for t(4;11) and RAS
mutations.
Methods
Patients
Bone marrow or peripheral blood samples from 124 infants
(<12 months old) diagnosed with either pro-B or pre-B-cell ALL
were used in this study. The discovery cohort of patients was
composed of 42 de novo cases: 27 with the t(4;11) encoding for
MLL-AF4, five with the t(9;11) encoding for KMT2A-MLLT3
(MLL-AF9) and ten without MLLr (non-MLL B-other BCP-ALL
without numerical or structural chromosomal abnormalities
reported at diagnosis). Additionally, for eight MLL-AF4+ iBCP-ALL
patients matched diagnostic-relapse samples were available allow-
ing for longitudinal studies. MLL rearrangements were confirmed
by fluorescence in-situ hybridization.31,32 For validation, an addi-
tional cohort of patients, comprising 43 MLL-AF4+, 11 MLL-AF9+,
and 28 non-MLL iBCP-ALL cases, was used. All patients were
enrolled in the Interfant99 treatment study. Bone marrow samples
were collected at Erasmus MC-Sophia Children’s Hospital
(Rotterdam, the Netherlands), Armand Trousseau Hospital (Paris,
France), and San Gerardo Pediatric Hospital (Monza, Italy).
Complete remission bone marrow samples were available for all
patients. The clinical and genetic features of the patients are pre-
sented in Online Supplementary Table S1. As a control for the RNA-
sequencing studies, CD34+CD19+ healthy B-cell progenitors were
purified by fluorescence-activated cell sorting (FACS) from 22-
week old human fetal livers (FL) as previously described.32 FL
hematopoietic stem and progenitor cells (HSPC) were processed
and FACS-purified from second trimester human FL as previously
described.33 Briefly, cells were processed and stained for flow
cytometry with up to ten fluorophore-conjugated monoclonal
antibodies [antibodies (clone): CD34PECy7 (8G12), CD45RA
FITC (HI100), CD19APC (HIB19), CD123PE (9F5), CD90 PECy5
(5E10), CD38 Pacific blue (HIT2), lineage cocktail APC (CD2
(RPA-2.10)/CD3 (OKT3)/CD14 (61D3)/ CD16(CB16)/ CD19
(HIB19)/CD56 (TULY56)/CD235a (HIR2)]. FACS was performed
using a BD FACSAria II (Becton Dickinson). Gates were set with
unstained and fluorescence minus one controls, on viable cells.
Data were analyzed using FlowJo software (Tree Star). Gating
strategies are as described in the results section. The study was
approved by the Barcelona Clinic Hospital (2013/8529) and
Hammersmith and Queen Charlotte’s Hospital (04/Q0406/145)
research ethics committees.
Statistical analysis
For quantitative variables, a one-tailed t-test was used to identi-
fy significant differences between groups.  For qualitative vari-
ables, a Fisher exact test was used in order to identify significant
differences between groups of patients. Software for analysis of
mutations and gene expression have their own statistical models
explained in detailed in the references. Where multiple tests were
performed the significance is shown corrected for multiple testing.
Mutation allele frequency evolution was plotted with the R pack-
age distribution Fishplot. Patterns Fisher exact test was used to
assess the association between clinical characteristics and pres-
ence of RAS mutations or AF4-MLL expression. Event-free sur-
vival was defined as time from diagnosis to first event, i.e. resist-
ance, relapse, death from any cause, or second malignant neo-
plasm. Observation periods were censored at the time of last con-
tact when no events were reported. Event-free survival curves
were estimated with the Kaplan-Meier method and standard
errors (SE) were calculated according to Greenwood. Differences
in event-free survival and overall survival between groups were
compared with the log-rank test. Analysis of the prognostic rele-
vance of AF4-MLL/HOXA expression in combination with risk
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stratification according to the Interfant-06 protocol (based on age
at diagnosis, white blood cell count and response to prednisone)
was performed with the Cox model and the Wald test. All tests
were two-sided. Analyses were performed using SAS 9.2.
DNA, RNA and B-cell receptor (VDJ) repertoire
genome-wide analyses and data analysis
Preparation and analysis of all DNA and RNA genome-wide
high-throughput sequencing is detailed in the Online
Supplementary Methods, Online Supplementary Figure S1 and Online
Supplementary Table S2.
Results
At diagnosis infant B-cell precursor acute 
lymphoblastic leukemia shows a silent mutational
landscape irrespective of MLL gene status
Whole-exome sequencing and whole-genome sequenc-
ing analyses showed a silent mutational landscape in the
three iBCP-ALL subtypes studied here: MLL-AF4+, MLL-
AF9+ and non-MLL (n=42 patients, Online Supplementary
Table S1). Our study revealed an average of one genomic
rearrangement and 2.5 non-silent single nucleotide vari-
ants, a 2-fold higher number than that reported by
Andersson et al.,20 likely reflecting the 3-fold larger
sequencing coverage (Figure 1A, Online Supplementary
Figure S1 and Online Supplementary Table S3). All mutations
found at diagnosis were validated using orthogonal meth-
ods. This mutational frequency is the lowest described for
any other pediatric tumor type according to recent
reports34 (Online Supplementary Figure S2). Intriguingly, one
third of the mutations validated showed a mutant allele
frequency (MAF) <20% indicating that iBCP-ALL contains
genetically different intratumoral subclones despite its
genomic stability, likely explaining the higher mutational
load than that reported by Andersson et al.20 (Figure 1A
and Online Supplementary Table S3). Despite the paucity of
mutations, ~80% of the validated protein-coding muta-
tions (90/116) are predicted to produce deleterious effects
on the protein (Online Supplementary Figure S3A) which
might support a strong selective pressure in iBCP-ALL. To
gain insights into the molecular mechanisms underlying
the accumulation of mutations, we analyzed the enrich-
ment of specific mutational signatures as described by
Alexandrov et al.35 In the MLL-AF4+ iBCP-ALL subgroup
we identified a significant enrichment of signature 1 char-
acterized by the accumulation of C>T/G>A transitions,
linked to a spontaneous deamination of 5-methylcytosine
(Online Supplementary Figure S3B,C).35 This mutational sig-
A. Agraz-Doblas et al.
1178 haematologica | 2019; 104(6)
Figure 1. Somatic mutations detected by whole-exome sequencing in the discovery cohort of infant B-cell precursor acute lymphoblastic leukemia. (A) Total num-
ber of mutations identified in each individual patient. The total number of non-synonymous mutations (yellow area, right Y axis) and mutant allele frequency (MAF)
for each mutation (individual dots, left Y axis) are represented. (B) Oncodrive software identified the PI3K-RAS pathway as the only recurrently mutated pathway in
infant B-cell precursor acute lymphoblastic leukemia. The distribution of mutations in genes of the PI3K-RAS pathway is shown for all patients within the three iBCP-
ALL subgroups: [total 42 patients: 27 t(4;11)+, 5 t(9;11)+ and 10 MLLwt].
A
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nature has also been described in other pediatric tumors,
suggesting that iBCP-ALL is not subjected to a specific
mutational signature.
We also determined the molecular breakpoint of all
MLLr at the base-pair level. In t(4;11)/MLL-AF4+ iBCP-
ALL, the AF4 breakpoints were almost invariably localized
within intron 3 whereas MLL breakpoints were found
between introns 9 and 11 (Online Supplementary Table S4).3
We found whole-genome sequencing reads compatible
with an AF4-MLL reciprocal rearrangement in all samples
(Online Supplementary Figure S4). AF4-MLL genomic break-
points were validated by polymerase chain reaction capil-
lary sequencing and they were located nearby MLL-AF4
breakpoints, confirming a reciprocal chromosomal
translocation.
RAS-PI3K is the only recurrently mutated pathway 
in infant B-cell precursor acute lymphoblastic
leukemia with NRAS mutations being significantly
more frequent in t(4;11)+ patients
Despite the low number of mutations found per sample,
38% of the sequenced iBCP-ALL patients displayed acti-
vating/gain-of-function mutations in either KRAS or
NRAS. Additional mutations in other genes members of
the RAS-PI3K pathway such as FGFR4, JAK2, PTPN11,
SETD2, or FLT3were also identified (Figure 1B). To further
validate the unique recurrence of KRAS and NRAS muta-
tions, we performed targeted sequencing of these muta-
tions in a large, additional validation cohort of infant
patients (n=82) and confirmed that 34% of the iBCP-ALL
cases carry mutations in either KRAS or NRAS36 (Figure
2A). Interestingly, the overall frequency of RAS mutations
differed slightly between the different cytogenetic sub-
groups of iBCP-ALL, with the MLL-AF4+ subgroup show-
ing the highest frequency (42%) and the MLL-AF9+ sub-
group the lowest (19%). This difference was basically
attributed to the frequency of NRAS mutations, which
was 6-fold more common in the MLL-AF4+ subgroup
(32% vs. 6%, Fisher exact test P=0.01) (Figure 2A,B).
Surprisingly, we observed that many iBCP-ALL patients
had mutations in both KRAS and NRAS, or more than one
(different) mutation in the same gene (Figure 2A,C). To
further analyze the biological contribution of KRAS and
NRAS mutations, we calculated the MAF of individual
mutations and observed that the majority of patients who
had a single RAS mutation (either KRAS or NRAS) had
MAF scores between 0.20 and 0.45, suggesting that the
mutation is present in a major leukemic subclone
(P=0.0025). By contrast, those patients harboring two or
more RAS mutations displayed MAF scores between 1%
and 20%, compatible with these RAS mutations being in
distinct and smaller leukemic subclones. We then ana-
lyzed the impact of RAS mutations on disease outcome
and found no clinical correlation of RAS mutations with
either clinical outcome (overall survival, event-free sur-
vival, central nervous system infiltration) or diagnostic
parameters (gender, age, percentage of blasts and white
blood cells) (Online Supplementary Figure S5).
Evidence of clone selection and genomic instability 
at relapse
Paired diagnostic-relapse samples were available for
eight MLL-AF4+ iBCP-ALL patients, permitting longitudi-
nal studies. Whole-exome sequencing revealed an 8-fold
increase in the number of somatic non-synonymous
mutations at relapse (19.5 mutations/patient, range:1-434,
paired t-test P=0.03) (Figure 3A,B and Online Supplementary
Table S3). We performed orthogonal validation for 160
random mutations, and 90% and 75% of mutations with
MAF >15% and <15%, respectively, were confirmed (data
not shown). Similarly to diagnosis, the majority of the
somatic mutations found at relapse had MAF commonly
<30%, suggesting the existence of multiple leukemic sub-
clones (Figure 3A). Importantly, none of the new de novo
somatic mutations found at relapse was found in more
than one patient, likely reflecting an intrinsic genomic
Cellular origin and clinical prognostic markers of infant MLLr B-ALL
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Figure 2. Frequent somatic mutations in RAS genes in both the discovery and validation cohorts. (A) Specific KRAS and NRAS mutations recurrently found in each
patient by high coverage targeted sequencing. (B) Proportions of patients with mutations in KRAS (brown), NRAS (yellow) or both (gray) within the three infant B-cell
precursor acute lymphoblastic leukemia subgroups. (C) Mutant allele frequency of KRAS (brown squares) or NRAS (yellow circles) mutations in each individual
patient. Discovery cohort, n=42; validation cohort, n=82.
A
B C
instability of leukemic clones surviving induction/consoli-
dation chemotherapy. This is further reflected by a signif-
icant enrichment of signature 6 associated with defective
DNA mismatch repair, including a higher number of small
indels, observed in MLL-AF4+ patients at relapse (Online
Supplementary Figure S6A).
To delineate the evolutionary clonal structure from diag-
nosis to relapse, we performed high-coverage targeted
sequencing on the identified mutations in paired diagnos-
tic-remission-relapse samples.37 Importantly, the main
leukemic clone at relapse was always present at diagnosis
although in some cases with a very low MAF, suggesting
a chemotherapy-induced clonal pressure selecting for
resistant/adapted leukemic subclones (Figure 3C).
A. Agraz-Doblas et al.
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Figure 3. Clonal evolution and
genomic instability at relapse. (A)
Total number of mutations identified
for each patient in paired diagnostic-
relapse samples. Total number of
non-synonymous mutations (yellow
area, right Y axis) and mutant allele
frequency (MAF) for each mutation
(individual dots, left Y axis) are repre-
sented for paired diagnostic and
relapsed (R) samples. (B) Circos plot
representation of the total number of
mutations identified at diagnosis and
relapse for a representative patient
(MA4_17). Genomic rearrangements
are represented by lines connecting
both breakpoints. Copy number alter-
ations (blue=gains, red=losses) are
represented by the outer gray circle.
Somatic mutations (both single
nucleotide variants and indels) are
depicted in the center of the circle
and the affected gene is indicated. (C)
Graphic representation of clonal evo-
lution in paired diagnostic (DX)-
relapsed (RL) samples. The number of
unique somatic mutations called at
diagnosis (orange), relapse (yellow) or
shared between DX and REL (red) are
indicated. Bigger gene names indicate
higher MAF for the mutations shared
at DX and REL. (D) Dynamics of RAS-
mutated clones identified as MAF in
matched DX-Remission-REL trios
(n=8).
A
B
C
D
Interestingly, we found a correlation between the number
of mutations and time to relapse in MLL-AF4+ patients,
with a trend towards a higher mutational load in patients
with late relapses (Online Supplementary Figure S6B). We
next analyzed the clonal evolution of RAS-mutated
leukemic clones at relapse. We found that the contribution
of the RAS mutations varied among patients: one-third of
the iBCP-ALL patients had RAS-mutated clones at relapse
(MA4_20 and MA4_22 increased the size of the RAS-
mutated initial clone and in MA4_14 a de novo RAS muta-
tion emerged), whereas it was lost in two-thirds of the
patients (MA4_17, MA4_18, MA4_23, MA4_24) (Figure
Cellular origin and clinical prognostic markers of infant MLLr B-ALL
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Figure 4. Transcriptional signature of
infant B-cell precursor acute lym-
phoblastic leukemia samples. (A)
Heatmap representing FLT3, PROM1,
MEIS1 and HOXA gene expression
according to the infant B-cell precur-
sor acute lymphoblastic leukemia
(iBCP-ALL) cytogenetic group and RAS
mutations. (B) Top panel: heatmap
showing HOXA cluster gene expres-
sion according to the expression of
the reciprocal fusion AF4-MLL.
Bottom panel: quantitative poly-
merase chain reaction validating high
expression of HOXA cluster genes in
t(4;11) iBCP-ALL patients expressing
AF4-MLL. (C,D) Four-year event-free
survival (C) and overall survival (D)
Kaplan-Meier curves for t(4;11) iBCP-
ALL patients according to AF4-MLL
expression, n=43 t(4;11)+ patients.
(E) Heatmap representation of select-
ed genes for the signaling pathways
most significantly deregulated. Right
panels represent positive pathway
enrichment called by gene set enrich-
ment analysis software. Total 42
patients: 27 t(4;11)+, 5 t(9;11)+ and
10 MLLwt.
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3D). This indicates that infants with MLL-AF4+ BCP-ALL
relapse irrespective of the status of KRAS and NRAS.
Thus, subclones carrying KRASmutations do not exert an
advantage over non-mutated clones, despite representing
a recurrent genetic insult at diagnosis. Hence, this would
argue against a leukemia-initiating role for RAS
mutations.38 Alternatively, RAS mutations might indeed
be leukemogenic drivers, but the treatment-induced
genetic instability observed at relapse may compensate de
novo RASmutations, acting as new leukemia drivers coop-
erating with MLL-AF4 during relapse.
HOXA cluster genes are only expressed in t(4;11)+
patients expressing the reciprocal fusion AF4-MLL
which determines clinical outcome
To gain insights into the mechanisms underlying leuke-
mogenesis in these mutationally silent MLLr and MLL
germline iBCP-ALL patients, we performed RNA-
sequencing in the discovery cohort of patients (n=42)
using FL-derived CD34+CD19+ healthy B-cell progenitors
as controls, as these cells most likely represent the healthy
counterparts of the leukemic blast stalled at the pro/pre-B-
cell differentiation stage. We first surveyed the expression
of the genes previously reported to be specific to either
MLLr iBCP-ALL or specifically to MLL-AF4+ iBCP-ALL39.
RNA-sequencing profiling confirmed that these genes seg-
regate patients according to the molecular subtype, MLL-
AF4+, MLL-AF9+ and MLL germline (Online Supplementary
Figure S7). We also observed, at diagnosis, a strong upreg-
ulation of the MLL target genes FLT3,40 MEIS1, PROM1
and HOXA genes in many of our MLLr iBCP-ALL samples
but not in MLL germline samples (t-test, P<0.05) (Figure
4A), thus validating our RNA-sequencing approach. 
Strikingly, the reciprocal AF4-MLL fusion gene was dis-
cernibly expressed in 19/43 (45%) of the t(4;11)+ iBCP-
ALL samples, and its expression was always maintained at
relapse (data not shown). We then compared the genes dif-
ferentially expressed between AF4-MLL-expressing and
non-expressing t(4;11)+ patients and found a striking posi-
tive correlation between the expression of the HOXA gene
cluster and overexpression of the reciprocal AF4-MLL
fusion (t-test, P=0.002) (Figure 4B). These AF4-
MLL/HOXA-expressing patients (n=19) had a significantly
better prognosis than those lacking AF4-MLL/HOXA
expression (n=24). Four-year event-free and overall sur-
vival rates were 62.4% (SE, 11.3%) versus 11.7% (SE,
10.2%) (P=0.001) (Figure 4C), and 73.7% (SE, 10.1%) ver-
sus 25.2% (SE, 10.3%) (P=0.016) (Figure 4D), respectively.
When “AF4-MLL expression” was analyzed in a Cox
model adjusting for risk stratification (medium risk or high
risk according to the Interfant-06 protocol based on age at
diagnosis, white blood cell count and response to pred-
nisone), it retained its prognostic significance with a haz-
ard ratio for patients lacking AF4-MLL expression of 3.42
[95% confidence interval (95% CI): 1.35-8.63; P=0.01)
compared to those expressing AF4-MLL/HOXA, while
risk group was not significant (HR for high risk vs. medi-
um risk, 1.34; 95% CI: 0.59-3.03; P=0.49). This is the first
study showing that AF4-MLL overexpression correlates
very well with transcriptional deregulation of the HOXA
gene cluster in iBCP-ALL and that the co-expression of
AF4-MLL and HOXA gene cluster identifies a subgroup of
t(4;11)+ iBCP-ALL with a very more favorable clinical out-
come.
We next explored new molecular pathways involved in
the pathogenesis of iBCP-ALL, by performing an unbiased
transcriptional analysis of the RNA-sequencing data from
the iBCP-ALL patients. We found deregulated expression
of a total of 3,905 genes, of which 2,575 (66%) were
upregulated and 1,330 (34%) downregulated as compared
with those of healthy FL-derived B-cell progenitors, illus-
trating the global transcriptional activation nature of MLL
fusions (Online Supplementary Figure S8).25,41 Furthermore, a
significant upregulation of genes involved in the control of
cell growth, including the CDK inhibitors P21, P16, P19,
P27 and components of the transforming growth factor-b
pathway such as TGFB1, SMAD and ACVR1B, was
observed in iBCP-ALL (Figure 4D and Online
Supplementary Figure S9). By contrast, iBCP-ALL showed a
robust downregulation of genes involved in DNA integri-
ty checkpoints such as CHEK1, CHEK2, ATM, ATR and
RAD17, and in double-strand break repair genes including
ERCC4, BRCA1, POLA1 and RAD51 (Figure 4E and Online
Supplementary Figure S9). These transcriptional changes
were validated by quantitative reverse transcriptase poly-
merase chain reaction in ten patients per group (Online
Supplementary Figure S10). Deregulation of DNA integrity
checkpoints and double-strand break repair genes may
well contribute to the genomic instability observed at
relapse, and might explain the enrichment in C>T/G>A
transitions, associated with the spontaneous deamination
of 5-methylcytosine (Online Supplementary Figures S3 and
S6).
By using FL-derived normal B-cell progenitors as con-
trols, differences between leukemic blasts and their nor-
mal counterparts could be identified but this does not
allow the definition of transcriptomic differences within
the iBCP-ALL cytogenetic groups. We, therefore, analyzed
the RNA-sequencing data comparing the genes differen-
tially expressed in MLL-AF4+ versus MLL-AF9+ and MLL-
wildtype iBCP-ALL patients, without considering normal
B-cell progenitors as controls. A gene ontology analysis
(gene set enrichment analysis, GSEA) performed with the
genes differentially expressed revealed that MLL-AF4+
patients show, as compared to both MLL-AF9+ and MLL-
wildtype patients, a significant upregulation of genes asso-
ciated with cellular catabolism, coupled to a significant
downregulation of negative regulators of the PI3-MAPK
pathway, as well as of genes involved in lymphoid differ-
entiation and RNApol II transcriptional regulation (Figure
5). This suggests, respectively, a metabolic change in MLL-
AF4+ cells towards rapid energy generation while reinforc-
ing the basal hyperactivation of the PI3-MAPK pathway
by RASmutations (Figures 1 and 2), a poorly differentiated
cellular origin of t(4;11), and an impairment of the normal
function of AF4, a key component of the RNApol II tran-
scription complex.
Deep-sequencing analysis of B-cell receptor 
repertoires suggests a hematopoietic stem cell/early
pre-VDJ progenitor as the cell-of-origin for t(4;11) 
and RAS mutations
We next analyzed BCR repertoires to gain insights into
the immunoglobulin heavy chain (IgH) rearrangement
clonal composition of paired diagnostic-relapse samples
from t(4;11)+ iBCP-ALL (4 pairs). BCR are generated
through DNA recombination during B-cell differentiation
and represent unique markers for each B-cell clone.
Because the BCR sequence provides a molecular tag for
each B-cell clone, high-throughput sequencing of BCR
A. Agraz-Doblas et al.
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provides a detailed analysis of B-cell population dynamics
and clone tracking.42,43 BCR sequencing was therefore per-
formed to address whether t(4;11)+ iBCP-ALL cells
expressed fully rearranged BCR from which increased lev-
els of B-cell clonal expansion may be observed and to
determine whether there are detectable levels of B-cell
clonal persistence over time indicative of B-cell clonal sur-
vival. BCR sequencing was performed on t(4;11)/MLL-
AF4+ iBCP-ALL peripheral blood samples (blasts >98%)
using a polymerase chain reaction-based method37 with
additional incorporation of unique molecular barcodes,
allowing for accurate quantitation of relative B-cell clone
frequency. After BCR sequence filtering, each sample
yielded between 1,583-46,863 BCR (1,213-38,426 unique
BCR) (Online Supplementary Table S5).
We first delineated the relative clonality in these
patients, and found that the BCR repertoires from t(4;11)+
patients did not exhibit significantly expanded VDJ-
rearranged B-cell clones (Figure 6A) either at diagnosis or
relapse compared to healthy peripheral blood samples
(Figure 6B). This is in contrast to non-MLL BCP-ALL
patients (n=5) including three patients with t(1;19)/TCF3-
PBX1 (EF2-PBX1), one with t(12;21)/ETV6-RUNX1 (TEL-
AML1) and one with t(9;22)/BCR-ABL1, which were all
found to be significantly clonal, with large B-cell clones
comprising ~3-40% of total BCR (Figure 6B,C).37 Given
the persistence of both t(4;11) and RASmutations in MLL-
AF4+ iBCP-ALL, the lack of B-cell clonal expansion or per-
sistence supports the model that t(4;11)/MLL-AF4+ iBCP-
ALL malignant cells are developmentally stalled at the pro-
B stage, and that the cellular origin of such genomic driv-
ers has to be pre-VDJ stem/progenitor cells. 
Finally, in order to understand whether the fetal cell-of-
origin in iBCP-ALL lies upstream of committed B progen-
itors, we compared the transcriptome of iBCP-ALL blasts
(n=42) with that of highly purified human FL HSPC pop-
ulations (3-7 for each population) (Figure 7A,B and Online
Supplementary Table S6) by RNA-sequencing. In keeping
with the results of the BCR analysis, our principal compo-
nent analysis revealed a gene expression signature for
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Figure 5. Specific transcriptional
differences between MLL-AF4+
and MLL-AF9+ or MLLwt infant B-
cell precursor acute lymphoblas-
tic leukemia patients. Here, FL-
derived CD34+CD19+ progenitors
were not included as normalizers
in the analysis in order to avoid
potential bias. Gene set enrich-
ment analysis (GSEA) was per-
formed with the genes differen-
tially expressed between MLL-
AF4+ patients and MLL-AF9+ or
MLLwt patients. MLL-AF4+ infant
B-cell precursor acute lym-
phoblastic leukemia (iBCP-ALL)
patients showed a significant
overexpression of genes associ-
ated with cellular catabolism,
coupled to a significant downreg-
ulation of negative regulators of
the PI3-MAPK pathway, as well
as of genes involved in lymphoid
differentiation and RNApol II
transcriptional regulation as
compared to both MLL-AF9+ and
MLLwt iBCP-ALL patients. The
bottom panels represent positive
pathway enrichment called by
GSEA software. Total 42
patients: 27 t(4;11)+, 5 t(9;11)+
and 10 MLLwt.
primitive Lin-CD34+CD38-CD19- FL HSPC (hematopoietic
stem cells, multipotent progenitors, and lymphoid-primed
multipotent progenitors, which lie upstream of B progen-
itors) very similar to t(4;11)+ iBCP-ALL, while FL-commit-
ted B progenitors clustered as a transcriptionally different
entity (Figure 7C).
Discussion
We set out to perform multi-layered sequencing on a
large cohort iBCP-ALL patients, all enrolled in the interna-
tional, collaborative Interfant treatment protocol. The fact
that all patients were identically treated provides legitima-
cy and confidence in potential correlations of clinical
value. Our study revealed an average of 2.5 non-silent sin-
gle nucleotide variants, a 2-fold higher number than that
reported by Andersson et al.,20 likely reflecting the 3-fold
larger sequencing coverage. This silent mutational land-
scape, even in non-MLL iBCP-ALL, likely reflects the very
young age of these patients, reinforcing the notion that
infant cancer is a developmental disease with not enough
time to develop somatic mutations. We also found the
only recurrent, but subclonal, mutations occur in the
KRAS and NRAS genes (gain-of-function mutations),
although the frequency of subclonal NRAS mutations is
significantly higher in t(4;11)+ patients. In line with our
previous work we found no recurrent mutations in the
FLT3 gene.40
Analysis of clonal evolution of RAS-mutated clones
from diagnosis to relapse revealed that one-third of the
patients still carry RAS mutations at relapse, whereas the
other two-thirds of patients who relapse have lost the
diagnostic RAS mutation. This is in accordance with
recently published data by Trentin et al.,36 and suggests
that the therapy is able to eliminate the RAS-mutated
clone in some patients, while in other patients the RAS
mutation seems to confer chemoresistance, allowing these
clones to evade treatment.44 Intriguingly, ~25% of the
patients carry more than one RAS-mutated clone at diag-
nosis, indicating a selection bias towards mutations in the
RAS genes, or activated RAS pathways during leukemic
transformation. From this perspective, the occurrence of
patients carrying multiple distinct clones with activated
RAS pathways may point to convergent evolution of
clones capable of controlling the proliferation rate.
However, arguing against this is the substantial represen-
tation of patients not carrying RAS mutations at all.
Hence, the role of RAS mutations in t(4;11)+ iBCP-ALL
remains obscure, and the available data suggest that RAS
pathway mutations are unlikely leukemia-initiating
lesions. Indeed, Tamai et al.45 showed that leukemogenesis
A. Agraz-Doblas et al.
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Figure 6. Analysis of B-cell
receptor repertoires suggest a
hematopoietic stem cell/early
pre-VDJ progenitor as the cell-
of-origin for t(4;11)/MLL-AF4+
infant B-cell precursor acute
lymphoblastic leukemia. (A)
Cloud-plots of B-cell receptor
(BCR) repertoires from two rep-
resentative t(4;11)+ infant B-cell
precursor acute lymphoblastic
leukemia (iBCP-ALL) patients
depicting the existence of many
minor non-expanded B-cell
clones either at diagnosis or
relapse. Each vertex represents
a unique BCR sequence, and
the relative vertex size is propor-
tional to the number of identical
reads. (B) Largest BCR clone
size in t(4;11)+ iBCP-ALL,
healthy individuals and non-
t(4;11)+ pediatric BCP-ALL. (C)
Cloud-plots of BCR repertoires
of representative t(1;19)/E2A-
PBX1+, t(12;21)/TEL-AML1+ and
t(9;22)/BCR-ABL+ patients
showing high clonality of B-cell
clones. The samples from the
iBCP-ALL patients who were
BCR-sequenced were four MLL-
AF4+ diagnostic-relapse pairs,
three E2A-PBX1+ samples, one
TEL-AML1+ sample and one
BCR-ABL+ sample.
A B
C
of transgenic mice expressing human MLL-AF4 could be
significantly accelerated by KRAS mutations. However,
although activated KRAS did cooperate with MLL-AF4 in
human cord blood-derived CD34+ HSPC to promote
extramedullary infiltration and central nervous system
infiltration it failed to initiate leukemia in engrafted mice.27
Importantly, we report a lack of correlation between RAS
status and parameters associated with diagnosis or disease
outcome such as overall survival, event-free survival, cen-
tral nervous system infiltration, gender, percentage of
blasts and white blood cells and age, further supporting
the concept that RAS mutations are not leukemia-initiat-
ing/propagating lesions.
Clearly, this brings us back to the central question of
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Figure 7. Comparison of the transcriptome of human fetal
CD34+ hematopoietic stem and progenitor cell populations to
infant B-cell precursor acute lymphoblastic leukemia. (A)
Schematic representation of B-cell development in human fetal
liver (FL) showing immunophenotypic definitions for hematopoi-
etic stem cells (HSC), multipotent progenitors (MPP), lymphoid-
primed multipotent progenitors (LMPP), committed B progeni-
tors (CBP) and B cells. The onset and expected patterns of IgH
rearrangements59,60 are depicted as red arrows. (B) Sorting strat-
egy for FL hematopoietic stem and progenitor (HSPC) popula-
tions by fluorescence-activated cell sorting. The sorting gates for
each population are shown in representative flow plots on the
left. The purity of the sorted populations is depicted on the right
demonstrating >95% purity. (Lin, Lineage cocktail). (C) Principal
component analysis of gene expression of infant B-cell precursor
acute lymphoblastic leukemia (iBCP-ALL) samples (n=42) and FL
HSPC populations (n=3-7) using the top 1,000 variably
expressed genes, as determined by RNA-sequencing. FL HSPC
as in (A); MAF4, MLL-AF4+ iBCP-ALL; MA9, MLL-AF9+ iBCP-ALL;
MLLwt, MLL wildtype iBCP-ALL.
A
B
C
whether or not MLL-AF4 by itself is sufficient to initiate
BCP-ALL in humans. The silent mutational landscape
observed in this study and by others20 certainly votes in
favor of MLL-AF4+ iBCP-ALL being initiated by a single
“big-bang” transformation hit, probably in a short-lived
but highly proliferative prenatal B-cell progenitor.4 This
hypothesis is supported by recent work by Lin et al., who
indeed demonstrated that enforced expression of a fusion
transcript consisting of human MLL and murine Af4 in
cord blood-derived CD34+ HPSC is sufficient to induce
pro-B ALL in xenografted immunodeficient mice.21,22 Yet,
similar results using a human MLL-AF4 transcript remain
to be established.
Although MLL-AF4 by itself may be sufficient to induce
BCP-ALL without significant contributions from coopera-
tive genetic lesions, the contribution of the MLL-AF4 and
RAS mutations to leukemogenesis should take into
account the nature of both the fetal target cell for transfor-
mation and the leukemia-initiating cell, according to the
increasingly accepted stochastic stem cell model of B-
ALL.46,47 Here, we employed high-throughput BCR-
sequencing of the IgH locus to delineate the dynamics of
clonality of B-cell populations in paired diagnosis-relapse
samples of t(4;11)/MLL-AF4+ iBCP-ALL. While pediatric
patients with E2A-PBX1+, TEL-AML1+ and BCR-ABL1+ B-
ALL all had significantly clonal disease, with a major VDJ
rearranged B-cell IgH clone accounting for up to 40% of all
BCR, infants with MLL-AF4+ BCP-ALL exhibited a BCR
repertoire composed of thousands of minor, non-expanded
VDJ rearranged IgH B-cell clones. Because MLL fusions are
clonal and RAS mutations are found in clones of relative
big size, this suggests that MLL fusions with or without
RASmutations are likely to originate in primitive fetal pro-
genitors that have a germline or an incompletely
rearranged (DJ) IgH locus.48 Indeed, an unsupervised com-
parison of the transcriptome of FL HSPC populations and
iBCP-ALL blasts suggests that while the gene expression of
primitive FL HSPC (Lin-CD38-CD34+CD19- populations) is
similar to that of iBCP-ALL, FL B progenitors
(CD34+CD19+) are transcriptionally distinct. Our data ele-
gantly reinforces previous fluorescence in-situ hybridiza-
tion findings suggesting that a primitive “pre-VDJ”
stem/progenitor cell (perhaps CD34+CD19-) may represent
the cell in which both t(4;11) and RASmutations arise.14,31,49
Cooperative leukemogenic events in iBCP-ALL may
need to be sought beyond genetic insults; for instance, epi-
genetic and transcriptomic deregulation. MLL-AF4 might
only induce BCP-ALL in cells that meet certain epigenetic
and transcriptomic make-up criteria, either influenced by
microenvironmental cues, or characteristic of the cell-of-
origin.31 Indeed, lesions such as RAS mutations may con-
tribute to disease pathogenesis only against certain intrin-
sic epigenetic or transcriptomic backgrounds present in
the cell in which the MLL translocations occurred50,51. This
is supported by the limited impact of RAS mutations in
transcriptomic signatures associated with leukemia origin,
development and pathogenesis, although this is likely due
to the subclonal nature of RAS mutations.38 However, in
line with the reported contribution of RAS mutations to
extramedullary infiltration of MLLr BCP-ALL blasts,27
RAS-mutated patients displayed a transcriptomic signa-
ture associated with migration.
The functional and molecular contribution of the recip-
rocal fusion genes resulting from the derivative translo-
cated chromosomes remains obscure in cancer. The AF4-
MLL genomic fusion was previously detected in 80-85%
of t(4;11)+ patients.5,52 Our “multi-layered omics”
approach allowed for the exact characterization of the
t(4;11) molecular DNA/RNA break points and the identi-
fication of those patients expressing the reciprocal AF4-
MLL fusion. We now report that the AF4-MLL reciprocal
fusion is expressed in only 50% of t(4;11)+ iBCP-ALL
patients. Strikingly, there was a previously unrecognized
and very significant positive correlation between the
upregulation of the HOXA gene cluster and the expres-
sion of AF4-MLL. Of note, a recent study showed that
approximately half of t(4;11)+ patients do not have an
activated HOXA signature.44,53,54 Furthermore, in the
recent MLL-Af4-induced B-ALL xenograft model MLL-
Af4 failed to bind to HOXA genes and therefore HOXA
gene expression was not upregulated.21 This is experi-
mentally supported by chromatin immunoprecipitation-
sequencing analysis performed in human embryonic stem
cells transduced with MLL-AF4, AF4-MLL or both show-
ing a significant enrichment of H3K79 methylated regions
specifically associated with HOX-A cluster genes in dou-
ble fusion-expressing hematopoietic derivatives, estab-
lishing a functional and molecular cooperation between
MLL-AF4 and AF4-MLL fusions during human
hematopoietic development (data not shown). Strikingly,
AF4-MLL-expressing patients had a 5-fold longer event-
free survival and a 3-fold longer overall survival compared
to t(4;11)+ iBCP-ALL patients lacking AF4-MLL expres-
sion, which is in line with previous reports suggesting
that high HOXA gene expression is associated with
improved survival and lower risk of relapse.22,39 Because
the expression of AF4-MLL is not analyzed in routine
molecular diagnosis, our “multi-layered omics” approach
was critical to unraveling the association between AF4-
MLL and HOXA expression, thus identifying a novel sub-
group of t(4;11)+ iBCP-ALL with better clinical outcome.
It is very important for routine diagnostic and clinical
practice that when the expression of AF4-MLL was eval-
uated in a Cox model adjusting for risk stratification
(medium risk or high risk according to the Interfant-06
protocol), it retained its prognostic significance.
Mechanistically, AF4-MLL contains the SET domain dis-
rupted from its "specification domain", the N-terminal
portion of MLL, which binds to MEN1 and LEDGF thus
shaping the gene-targeting module of the MLL gene.
When AF4-MLL is expressed, the N-terminal portion is
substituted by the AF4 N-terminus (AF4N) which is the
crucial domain for binding to and strongly activating RNA
polymerase II (RNAP II) for transcriptional elongation.
Thus, expression of A4M-MLL may induce robust RNAP
II-dependent gene transcription by overwriting the elon-
gation control process in a dominant fashion.55–58 We
hypothesize that a likely function of AF4-MLL could be to
prepare the ground for MLL-AF4 or other transcription
factors to skew normal and leukemic hematopoietic cell
fate decisions. This also explains why MLL-AF4, but not
AF4-MLL, seems to be necessary in 100% of patients.  
Despite being a developmental cancer, iBCP-ALL
patients did not show reactivation of pluripotent or
embryonic-like gene expression signatures as revealed by
RNA-sequencing. Additional research is required to deci-
pher the nature of the insults initiating MLLr iBCP-ALL, as
so far we can only speculate on the data currently avail-
able. Whole-genome pyrosequencing will likely provide
unique insights into the DNA methylome landscape of
A. Agraz-Doblas et al.
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this mutationally silent iBCP-ALL. This study has clinical
implications in the diagnostic risk-stratification of t(4;11)+
iBCP-ALL.
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